Aurum Resources Ltd (ASX:AUE) managing director Dr Caigen Wang has strengthened his commitment to the company by investing $840,000 in Aurum through the purchase of 1.4 million shares at $0.60 per share.
The investment follows shareholder approval at the company's general meeting on June 9, 2026 and comes on the same terms offered to cornerstone investor Perseus Mining Ltd and participants in Aurum's recently completed $28.8 million capital raising.
St George Mining Ltd (ASX:SGQ, FRA:S0G, OTC:SGQMF) has reported strong initial metallurgical testwork results from its Araxá Niobium and Rare Earth Project in Brazil, with flotation beneficiation producing separate high-grade niobium and rare earth concentrate streams from near-surface mineralisation.
The results are an important step for St George in demonstrating the project's potential to support a dual-commodity operation capable of producing both niobium and rare earth products from the same ore source.
Critical Resources Ltd (ASX:CRR, FRA:9S70) has confirmed the presence of a gold-antimony system at its Croesus Project in New Zealand's Reefton Goldfield after first-pass reconnaissance sampling returned assays of up to 13.3g/t gold and 6,990ppm antimony.
The results come from a program of rock-chip, float and historic ore-spillage sampling completed along the Croesus-Minerva trend, supporting the company's exploration model for a structurally controlled gold-antimony system hosted within Greenland Group metasedimentary rocks.
Pilbara Gold Ltd (ASX:PGL) has cleared a key milestone at its Roe Hills Gold Project in Western Australia's Eastern Goldfields, securing Aboriginal heritage approvals that pave the way for a substantial drilling program aimed at delivering a maiden resource estimate. The news comes just as the company has strengthened its board as work at Mt York also ramps up.
Pilbara Gold and the Ngadju Native Title Aboriginal Corporation recently completed a heritage survey covering the mineralised footprints at both Terra and Caliburn.
Experienced oncology drug development executive Dr Rosalind Wilson is joining Prescient Therapeutics Ltd (ASX:PTX) as chief medical officer, effective from July 13, 2026.
The appointment is expected to strengthen PTX's clinical and strategic capabilities as it advances its pipeline through key stages of development.